The impact of resveratrol on the outcome of the in vitro fertilization: an exploratory randomized placebo-controlled trial

Table 4 Ovarian stimulations outcomes, embryos and pregnancies between the two study groups

	Study Group n = 37	Control Group n = 33	p-value
Total gonadotropin dose (IU)	1973.61 ± 395.14	1907.89 ± 475.08	0.53
E₂ at peak (pg/ml)	1301 (996–2329.5)	1247 (901.5–1836)	0.53
Retrieved oocytes	7.89 ± 3.62	6.4 ± 3.84	0.1
M2 oocytes	6.26 ± 2.28	5.15 ± 2.7	0.1
Mature oocytes	0.89 (0.73–1)	0.88 (0.71–1)	0.76
FORT	0.92 (0.84–1)	0.77 (0.65–0.95)	0.02
FOI	0.77 (0.7–0.95)	0.64 (0.49–0.76)	0.006
OSI	4.44 (2.34–5.04)	2.86 (1.67–4.48)	0.25
Cleavage embryos/patient	2.16 ± 0.9	1.95 ± 1.14	0.39
Blastocysts/patient	1.47 ± 1.22	1 ± 1.21	0.11
Embryos transferred day 3	14/41 (34%)	15/39 (38.5%)	0.69
Embryos transferred day 5	23/41 (56%)	18/39 (46%)	0.37
Cryopreserved embryos/patient	0.79 ± 0.92	0.65 ± 0.93	0.53
Blastulation rate	0.3 (0.25–0.33)	0.25 (0.17–0.33)	0.45
BPR	9 (24.32%)	10 (30.3%)	0.57
CPR	9 (24.32%)	10 (30.3%)	0.57
LBR	6 (16.22%)	10 (30.3%)	0.16

FORT Follicle output rate, FOI Follicle oocytes indexm, OSI Ovarian sensitivity index, BPR Biochemical pregnancy rate, CPR Clinical pregnancy rate, LBR Live-birth rate
Parametric continuous data are presented as mean ± standard deviation
Non parametric continuous data are presented as median and interquartile range
Categorical variables are expressed in terms of frequency and percentage

ISSN: 1757-2215